The Community Research Advisors Group urges Sanofi to submit a bid for rifapentine to be included in the Stop TB Partnership's Global Drug Facility catalogue.

The Transactions of the Royal Society of Tropical Medicine and Hygiene published a Special Issue on implementing the End TB Strategy and the Sustainable Development Goals (SDGs).

Harm Reduction International releases a report identifying some of the most important human rights and public health standards relating to HIV, HCV and TB in prisons, and the vital role of harm reduction provision in ensuring them.

UNDP launches three new tools to strengthen the investment case for improved TB and malaria programming that addresses gender-specific vulnerabilities and needs.

Apply before February 12 if you want to be part of the Union Community Advisory Panel. The International Union Against Tuberculosis and Lung Disease is forming the Panel to improve community engagement within the organization.

Introducing bedaquiline and delamanid in TB programs worldwide has not kept pace with the need for these drugs. Coordinated global action might help assist making these medications accessible for persons who need them most.

U.S. Senators send letter urging President Obama to increase funding to allow full implementation of the National Action Plan for Combating Multidrug-Resistant Tuberculosis.  

In a joint declaration more than 80 leading international pharmaceutical, generics, diagnostics and biotechnology companies, as well as key industry bodies, call on governments and industry to work in parallel in taking comprehensive action against antimicrobial resistance.

NICE – the National Institute for Health and Care Excellence of England – published guidance on how to better treat and prevent tuberculosis. England has more TB cases than any other country in Western Europe.

The Lancet published a Series of five papers examining access to and sustainable effectiveness of antimicrobials.